Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VU369 is an oral dietary supplement developed and marketed by Allgems Healthcare. It is formulated with a combination of omega fatty acids, typically including omega-3, omega-6, and omega-9 fatty acids. These essential polyunsaturated and monounsaturated fats are critical for maintaining cell membrane integrity and serve as precursors to signaling molecules that modulate inflammatory responses and lipid metabolism. VU369 is primarily indicated for the support of cardiovascular health and as a general nutritional supplement to maintain healthy lipid levels and support heart and brain function. As a nutraceutical product, it is part of Allgems Healthcare's portfolio of branded generics and health supplements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VU369.